Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?

This publication has 20 references indexed in Scilit:

• American Tegumentary Leishmaniasis: Is Antimonial Treatment Outcome Related to Parasite Drug Susceptibility?
  The Journal of Infectious Diseases, 2006
• Resistance to Antimony and Treatment Failure in HumanLeishmania (Viannia)Infection
  The Journal of Infectious Diseases, 2006
• Sodium Antimony Gluconate Induces Generation of Reactive Oxygen Species and Nitric Oxide via Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Activation inLeishmania donovani-Infected Macrophages
  Antimicrobial Agents and Chemotherapy, 2006
• Drug Resistance in Leishmaniasis
  Clinical Microbiology Reviews, 2006
• Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models
  Zeitschrift Fur Parasitenkunde-Parasitology Research, 2005
• Antigen Genes for Molecular Epidemiology of Leishmaniasis: Polymorphism of Cysteine Proteinase B and Surface Metalloprotease Glycoprotein 63 in theLeishmaniadonovaniComplex
  The Journal of Infectious Diseases, 2004
• The In Vivo Susceptibility of Leishmania donovani to Sodium Stibogluconate Is Drug Specific and Can Be Reversed by Inhibiting Glutathione Biosynthesis
  Antimicrobial Agents and Chemotherapy, 2003
• Novel Intracellular SbV Reducing Activity Correlates with Antimony Susceptibility in Leishmania donovani
  Journal of Biological Chemistry, 2001
• Roles of Endogenous Gamma Interferon and Macrophage Microbicidal Mechanisms in Host Response to Chemotherapy in Experimental Visceral Leishmaniasis
  Infection and Immunity, 2000
• Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis.
  Journal of Clinical Investigation, 1989